You are here

  • Home
  • Archive
  • Volume 68, Issue Suppl 3
  • P230 Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: combined analysis from two 48-week studies

Citation Tools

Article menu

Download PDFPDF

Inhaled therapy in COPD
P230 Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: combined analysis from two 48-week studies
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Koch A, Paggiaro P, Hamilton A, et al
P230 Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: combined analysis from two 48-week studies
Thorax 2013;68:A180-A181.